Compare PAGSEG Inc (PAGS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs 10X Genomics Inc — how do they compare? PAGSEG Inc trades at $10.79 (market cap $2.94B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 3.4× PAGSEG Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 26 Days and 10X Genomics Inc for 92 Days on average.
| PAGS | TXG | |
|---|---|---|
Market Cap | $2.94B | $10.07B |
Volume | 4,242,708 | 5,657,286 |
Sector | Industrials | Health |
52-Week High | $12.00 | $97.74 |
52-Week Low | $8.44 | $11.48 |
Typical Hold Time | 26 Days | 92 Days |
Enterprise Value | $11.02B | $9.59B |
Dividend Yield | 10.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong profitability with a 10.45% net income margin and trades at a discounted valuation with a P/E of 7.1 and P/S of 0.74. Recent earnings beat expectations in Q2 2026, and a $0.28 dividend is scheduled for September 2026.
The outlook is positive given undervaluation, profitability, and dividend yield, but risks include a recent earnings miss in Q1 2026 and a projected negative net cash flow for 2026. Investor sentiment is supported by strong analyst buy ratings, though technical indicators show some overbought conditions with RSI at 78.08.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
